The effect of donor variation and senescence on endothelial differentiation of human mesenchymal stromal cells. by Portalska, K.K. et al.
1 
Janeczek Portalska et al.  1 
Running head: Donor variation in endothelial differentiation of hMSC 
 
The effect of donor variation and senescence on endothelial differentiation 
of human mesenchymal stromal cells 
 
Karolina Janeczek Portalska
1
, Nathalie Groen
2
, Guido Krenning
3
, Nicole Georgi
4
, 
Anouk Mentink
5
, Martin C. Harmsen
6
, Clemens van Blitterswijk
7
 and Jan de Boer
8, 9
 
 
1 MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Dreinerlolaan 5,  
7500 AE, Enschede, the Netherlands.  
tel. +31 53 489 3124, fax +31 53 489 2150; K.K.Janeczek@utwente.nl 
2 MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5,  
7500 AE, Enschede, the Netherlands.  
tel. +31 53 489 3049, fax +31 53 489 2150; N.Groen@utwente.nl 
3 Cardiovascular Regenerative Medicine Research Group (Cavarem),  
Dept. Pathology & Medical Biology, University Medical Center Groningen, University of Groningen 
Hanzeplein 1 (EA11), 9713GZ Groningen, The Netherlands 
tel. +31 50 361 5181 / +31 50 361 4776, fax +31 50 361 9911; g.krenning@umcg.nl 
4 MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5,  
7500 AE, Enschede, the Netherlands. 
tel. +31 53 489 3049, fax +31 53 489 2150; N.Georgi@utwente.nl  
5 MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5, 7500 AE,  
Enschede, the Netherlands. 
tel. +31 53 489 3202, fax +31 53 489 2150; A.Mentink@utwente.nl  
6 Cardiovascular Regenerative Medicine Research Group (Cavarem),  
Dept. Pathology & Medical Biology, University Medical Center Groningen, University of Groningen 
Hanzeplein 1 (EA11), 9713GZ Groningen, The Netherlands 
tel. +31 50 361 5181 / +31 50 361 4776, fax +31 50 361 9911; m.c.harmsen@umcg.nl 
7MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5,  
7500 AE, Enschede, the Netherlands. 
tel. +31 53 489 3275, fax +31 53 489 2150; c.a.vanblitterswijk@utwente.nl 
8 MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Drienerlolaan 5,  
7500 AE, Enschede, the Netherlands.  
tel. +31 53 489 3101, fax +31 53 489 2150; j.deboer@utwente.nl 
9 Corresponding author. 
 Page 1 of 37 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
Th
e 
ef
fe
ct
 o
f d
on
or
 v
ar
ia
tio
n 
an
d 
se
ne
sc
en
ce
 o
n 
en
do
th
el
ia
l d
iff
er
en
tia
tio
n 
of
 h
um
an
 m
es
en
ch
ym
al
 st
ro
m
al
 c
el
ls 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.06
46
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
2 
Janeczek Portalska et al.  2 
ABSTRACT 
Application of autologous cells is considered for a broad range of regenerative therapies 
because it is not surrounded by the immunological and ethical issues of allo- or xenogenic 
cells. However, isolation, expansion and application of autologous cells does suffer from 
variability in therapeutic efficacy due to donor to donor differences and due to prolonged 
culture. One important source of autologous cells are mesenchymal stromal cells (MSCs), 
which can differentiate towards endothelial-like cells, thus making them an ideal candidate as 
cell source for tissue vascularization. Here, we screened MSCs from 20 donors for their 
endothelial differentiation capacity and correlated it with the gene expression profile of the 
whole genome in the undifferentiated state. Cells of all donors were able to form tubes on 
Matrigel and induced the expression of endothelial genes, although with quantitative 
differences. In addition, we analyzed the effect of prolonged in vitro expansion on the 
multipotency of hMSCs and found that endothelial differentiation is only mildly sensitive to 
expansion-induced loss of differentiation as compared to osteogenic and adipogenic 
differentiation. Our results show the robustness of the endothelial differentiation protocol and 
the gene expression data give insight in the differences in endothelial differentiation between 
donors.  
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INTRODUCTION 
The use of allo- and xenogenic cells in regenerative therapies will always entail the possibility 
of graft rejection and the necessity of applying immunosuppressive therapy, which as a result 
will be a burden for patients. Therefore, most investigators in the field currently consider 
autologous cells as the most logical choice for study.  
Mesenchymal stromal cells (MSC), a much used source of autologous cells, can be isolated 
relatively easily from multiple sources including adipose tissue, tibia, femur, lumbar spine 
and trabecular bone [1-4]. They can be then expanded in vitro and are characterized by their 
multipotency. Among others they can differentiate into the adipogenic, osteogenic and 
chondrogenic lineages [5,6]. What is less well documented is the ability of MSCs to 
differentiate towards other cell types such as skeletal muscle cells and neural cells [7-9]. 
Moreover, it was shown lately that MSCs can also be a source of endothelial-like cells [10-
12], which would qualify them as candidate cells for therapies aimed at improved tissue 
vascularization, such as treatment of ischemic tissues and various strategies concerning large 
graft engineering.  
We and others have shown that when human MSCs are grown in endothelial differentiation 
medium, they express endothelial markers such as CD31, von Willebrand factor and VE-
cadherin, both at the mRNA and protein level [11-17]. In addition, the actively take up acidic 
LDL, another hallmark of endothelial cells. When grown on Matrigel, the cells will form 
tube-like structures. Moreover, when these cells are implanted in immune-deficient animals, 
CD31 positive human cells can be seen in the vessel wall of perfused blood vessels, 
demonstrating that human cells can functionally contribute to blood vessels. Nevertheless, 
further characterization of the cells is needed, and for that reason we refer to the cells as 
“endothelial-like cells”.     
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In order to apply MSC-derived endothelial-like cells, it is essential to establish a stable 
protocol for MSC isolation, culture and differentiation, because it will affect the therapeutic 
effect of the cells, as demonstrated previously for the application of MSCs in bone tissue 
engineering [18-20]. We have recently described a robust protocol to induce endothelial-like 
cells from bone marrow-derived MSCs in vitro and demonstrated their ability to contribute to 
the vasculature upon implantation in a mouse model. What remains to be addressed in order 
to bring endothelial-like MSCs to the clinic is both the large inter-donor variation in multi-
lineage potential [1,21] and the phenomenon of loss of multipotency upon culture expansion 
of MSCs. We and others have observed striking differences between hMSCs of different 
donors with regard to growth rate, expression of both lineage-specific and non-specific 
markers such as ALP and STRO-1 and their response to in vitro differentiation and ectopic 
bone formation [1,21-23]. Similar situation can occur upon endothelial differentiation which 
can explain the controversy concerning the ability of MSCs to acquire endothelial 
characteristics. A complicating fact is that therapeutic efficacy of MSCs is often not directly 
linked to marker gene or protein expression in vitro [24-26].  
Because the yield of hMSCs upon isolation is very low, expansion in culture is an essential 
step in their application. Unfortunately, this is associated with culture-induced loss of 
multipotency, as described by several researchers [1,27]. It was demonstrated that in vitro 
expanded MSCs acquire a phenotype characterized by loss of multipotency already at early 
passages [27-29] followed by replicative senescence at later stages of expansion. It appears 
that a hierarchy exists among the different lineages with respect to the number of population 
doublings at which loss of the particular differentiation route comes in effect [1,30].  
Although donor variability and loss of multipotency has been well-described for 
differentiation into the osteo- and adipogenic lineages, no such data is available for 
endothelial-like differentiation. To address this deficiency we have created a bank of MSCs 
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isolated from 62 donors (patients that were undergoing orthopedic surgery) and collected data 
about their in vitro expansion and differentiation capacity as well as their gene expression 
profiles. Using microarray study we have identified a diagnostic bone-forming classifier [23] 
capable of indicating the in vivo bone-forming capacity of hMSCs from different donors 
(unpublished data). In this manuscript, we have selected 20 donors of this bank and evaluated 
their propensity to differentiate into endothelial-like cells in order to sketch inter-donor 
variability and to evaluate whether gene expression in undifferentiated hMSCs correlated to 
it. Moreover, we have studied loss of endothelial-like differentiation potential during culture 
expansion and compared it to loss of adipo- and osteogenic differentiation.   
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MATERIALS AND METHODS 
Isolation and culture 
Human mesenchymal stromal cells (hMSCs) were isolated from human bone marrow from 
donors who provided us with written informed consent [31]. Aspirates were resuspended 
using a 20G needle and plated at a density 0.5 million mononucleated cells/cm
2
. Cells were 
grown in MSC proliferation medium which contains minimal essential medium (alfa-MEM, 
GIBCO) supplemented with 10% fetal bovine serum (FBS, Lonza), 100 U/ml penicillin 
(GIBCO), 10 g/ml streptomycin (GIBCO), 2 mM L-glutamin (GIBCO), 0.2 mM L-ascorbic 
acid 2-phosphate magnesium salt (ASAp, Sigma Aldrich) and 1ng/ml basic fibroblast growth 
factor (bFGF, Instruchemie) at 37C in a humid atmosphere with 5% CO2. Cells were 
expanded up to passage 2. For further experiments hMSCs from 23 different donors and one 
immortalized clone (iMSCs, courtesy of Ola Myklebost) were cultured in basic medium (alfa-
MEM supplemented with 10% FBS, 100 U/ml penicillin, 10 g/ml streptomycin, 2 mM L-
glutamin, 0.2 mM ASAp). Human umbilical vein endothelial cells (HUVEC, Lonza) were 
cultured in endothelial growth medium (EGM-2, Lonza).  
 
ALP analysis 
In order to analyze the activity of alkaline phosphatase, hMSCs from one donor were seeded 
at a density of 5,000 cells/cm
2
 in 6-well plates. Osteogenic medium (alfa-MEM, 10% FBS, 
100 U/ml penicillin, 10 g/ml streptomycin, 2 mM L-glutamine, 0.2 mM ASAp, 0.01 M 
BGP, 10
-8
 M dexamethasone) was changed twice a week and cells were cultured for 1 week. 
ALP activity was analyzed using the Sigma kit #85 per manufacturer’s instructions. Briefly, 
the culture medium was aspirated, cells were washed twice with calcium and magnesium free 
PBS and fixed in acetone/citrate. After washing in deionized water cells were stained with 
Fast Blue RR/naphthol. As a result naphthol AS-MX is liberated and immediately coupled 
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with a diazonium salt forming an insoluble, visible pigment at sites of phosphatase activity. 
Cells were photographed using a Nikon SMZ 10A camera.  
To confirm the results, an ALP biochemical assay (CDP-Star, Roche) was performed on 
selected samples. Briefly, cells were washed with PBS and lysed with lysis buffer (100mM 
potassium phosphate, pH 7.8, 0.2% Triton-X-100) for 10 min at room temperature. 10 l of 
the lysate was put in an optiplate together with 40 l of CDP-Star, incubated for 30 min in 
darkness at room temperature and then measured with a Victor Light Luminescence Plate 
Reader (Perkin Elmer). 
 
Adipogenesis 
Adipogenic differentiation capacity of hMSCs was determined as described previously [32]. 
Briefly, cells from one donor were cultured for three weeks in adipogenic medium (DMEM, 
10% FBS, 100 U/ml penicillin, 10 g/ml streptomycin, 0.5 mM IBMX, 1 M dexamethasone, 
10 M insulin, 200 M indomethacin). After that, lipid formation was visualized by staining 
with Oil red O. Cells were photographed using a Nicon Eclipse TE300 and the adipocytes 
were counted in the picture frame. At least 3 different locations of each well were included in 
the quantification.  
 
Endothelial induction of MSCs 
hMSCs from passage 3 and iMSCs from passage 25 were used for endothelial induction 
protocol as described previously [10]. Briefly, cells were seeded at a density of 3,000 
cells/cm
2
 on tissue culture plastic in EGM-2 and cultured for 10 days. After one day in static 
culture, shear force was applied using an orbital shaker. For induction on Matrigel, wells on 
6-well plates were covered with 1 ml of growth factor reduced Matrigel (BD Bioscience) 
diluted 1:1 in EGM-2 without growth factors. Cells were seeded at the density of 30,000 cells 
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per cm
2
 (60,000 cells per cm
2
 in case of HUVECs due to their smaller size) and cultured in a 
humid atmosphere with 5% CO2. After 24 hours of culture on Matrigel hMSCs start to 
express endothelial markers and are referred to as endothelial-like MSCs (EL-MSCs). 
 
Matrigel assay 
The assay was performed as described above. The formation of capillary-like structures 
(CLS) on Matrigel was observed over time using an inverted microscope (Nikon Eclipse 
TE300). Cells from all 20 donors were used in this study. Pictures were taken at different time 
points (4, 8, 16, 24, 48, and 96 hours after seeding) using a Nikon DS-L2 camera. The 
experiment was performed in triplicate.  
 
TubeCount 
Capillary-like structure formation was quantified based on images taken at a 24-hour time 
point using TubeCount software, as described previously [10]. As a result we gathered 
valuable statistics such as total and average tube length, average tube width, number of tube 
branching points and total tube area. A minimal number of 3 pictures per condition were 
analyzed. 
 
RNA isolation and quantitative PCR 
Total RNA was isolated using TRIZOL reagent according to manufacturer’s protocol. In 
short, 1 ml of Trizol reagent was added per T25 flask (cells cultured in basic medium) or per 
well (cells cultured on Matrigel in 6-well plates). Samples were incubated for 5 min at room 
temperature to allow complete dissociation, and phase separation was performed by adding 
chloroform. After that samples were centrifuged at 12,000 x g for 15 min. RNA was 
precipitated by mixing the aqueous phase with isopropyl alcohol followed by 10 min 
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incubation at room temperature. Samples were centrifuged again and the remaining RNA 
pellet was washed with 75% ethanol. The obtained samples were dissolved in water, and after 
that the quantity and quality of RNA was analyzed using spectrophotometry (ND-1000 
spectrophotometer). OD 260/280 nm ratios >1.8 were observed for all samples indicating high 
purity. 
500 ng of RNA was used for first strand cDNA synthesis using Superscript II (Invitrogen) 
according to the manufacturer’s protocol. One µl of 3x diluted cDNA was used for PCRs 
performed in a Light Cycler real time PCR machine (BioRad). Data was analyzed using Bio-
Rad iQ5 software and expression of endothelial genes was calculated relative to GAPDH 
levels by the comparative CT method [33]. Primers used in the study are: Platelet 
Endothelial Cell Adhesion Molecule-1 (CD31) F 5’ TCTATGACCTCGCCCTCCACAAA 3’, 
R 5’ GAACGGTGTCTTCAGGTTGGTATTTCA 3’; VEGF receptor 2 (KDR) 
F 5’ ACTTTGGAAGACAGAACCAAATTATCTC 3’, R 5’ TGGGCACCATTCCACCA 3’; 
von Willebrand factor (vWF) F 5’ TGCTGACACCAGAAAAGTGC 3’, 
R 5’ AGTCCCCAATGGACTCACAG 3’; GAPDH F 5’ CGCTCTCTGCTCCTCCTGTT 3’, 
R 5’ CCATGGTGTCTGAGCGATGT 3’. 
 
Microarray analysis 
To analyse the gene expression profile of hMSCs, microarray analysis was used. RNA was 
hybridized to the Human Genome U133A 2.0 Array (Affymetrix) and scanned with a 
GeneChip G3000 scanner (Affymetrix). To normalize the measurements, we used a 
normalization method which removes hybridization, amplification and array location based 
technical effects. Further data analysis and statistical testing were performed using R and 
Bioconductor statistical software (http://www.bioconductor.org/). A linear modelling 
approach with empirical Bayesian methods, as implemented in Limma package [34], was 
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used to determine differential gene expression. To analyse the donor variation in terms of 
endothelial differentiation ability, we scored the different donor-derived MSCs based on their 
CD31 expression on one hand and KDR expression on the other hand. Subsequently, a list of 
genes ranked on fold change between the best and poorest endothelial differentiating donors 
was generated.  
 
Statistics 
Each experiment was performed in triplicate. Data that required multiple comparison test was 
analyzed in SPSS (PASW statistics) using one-way Anova followed by Tukey’s multiple 
comparison test (P<0.05). Error bars on graphs represent standard deviation. 
 
Ethics statement 
Human mesenchymal stromal cells (hMSCs) were isolated from human bone marrow from 
donors with written informed consent. This study was carried out in strict accordance with the 
recommendations of the Medisch Ethische Toetsings Commissie Twente (Medical Ethical 
Research Committee Twente) and was approved by this Committee. 
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RESULTS 
hMSC characterization 
hMSC from our bank of 62 donors have been characterized previously (unpublished data) 
according to the set of standards proposed by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy [35]. In this manuscript, we have 
randomly selected 20 donors from the donor bank [1]. After defrosting and brief expansion, a 
subsection of cells of all donors were subjected to osteogenic and adipogenic differentiation. 
As shown in Supplementary Fig 1, MSCs from all donors readily acquired properties of 
adipocytes or osteoblast respectively, demonstrating their multipotency.  
 
Effect of culture expansion on multipotency of hMSCs 
We previously showed [1] that efficient differentiation of hMSCs is limited after prolonged 
expansion in vitro. To confirm these results, osteogenic and adipogenic differentiation of 
hMSCs from one donor was evaluated over 10 passages. Similar to previous observations, 
changes in cell morphology occurred during prolonged in vitro expansion (Fig 1A). hMSCs 
between passage 7 and 10 lost their fibroblast-like shape and acquired a more spread 
morphology. The cells in culture became larger, with irregular and heterogeneous contours. 
Moreover, hMSCs expanded in vitro lost their proliferation capacity over time, being unable 
to reach confluency even after prolonged culture (data not shown).     
To document osteogenesis, we measured dexamethasone-induced activity of the bone-maker 
alkaline phosphatase (ALP) [1]. Cells from passage 1 showed a 3 times higher activity of 
ALP than cells from passage 2 to 5 (Fig 1B) and ALP activity declined again three-fold in 
cells from passage 6 and higher (Fig 1B). A similar trend was observed for adipogenic 
differentiation (Fig 2A), where cells from passage 1 differentiated more efficiently than cells 
from passage 2 to 7. A gradual loss of adipogenic potential was observed (Fig 2B). Next, we 
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evaluated whether the endothelial differentiation capacity of hMSCs was lost as well upon 
culture expansion. In this case, we expanded cells from 2 donors (D42, D56) and first looked 
at their capacity to form tubes on Matrigel (Fig 3A). Overall, MSCs did not lose their capacity 
to form tubes, up to passage 7. At higher passages, we were unable to retrieve sufficient 
number of cells to perform the assay. In the case of donor 42, prolonged expansion led to 
shorter capillary-like structures, although the number of branching points seemed to increase. 
With cells from donor 56, we observed the opposite, with longer capillary like structure and 
fewer branching point at high passages. As a second readout of endothelial differentiation, we 
measured the expression of the endothelial marker CD31 in hMSCs exposed to proliferation 
medium and endothelial differentiation medium of three donors at various passage numbers. 
At passage 3, we observed induction of CD31 in all three donors, but this was completely lost 
in donor 57. Surprisingly, the cells of the other two donors were still able to induce CD31 
expression at passage 7, and even with a higher fold induction than at passage 3 (Fig 3B). Our 
data show that endothelial differentiation is not as sensitive to culture-induced loss of 
differentiation capacity as adipogenic and osteogenic differentiation are. 
 
Endothelial differentiation of hMSCs 
To investigate whether hMSC source (donor) influences endothelial differentiation, capillary-
like structure formation was observed on Matrigel. Tube formation was recorded by phase
 
contrast microscopy and pictures were used for further study. As shown in Fig 4A, cells from 
different donors performed with very different outcome. The quantification of CLS formation 
was performed using in-house developed TubeCount software. HUVECs were used as 
positive control in this assay and had a total tube length per analyzed area of 30 mm and more 
than 70 branching points. Measurement of these parameters with MSCs of 20 donors (Fig 4B) 
revealed that cells from all donors were able to form tube-like structures although substantial 
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inter-donor variation was seen, ranging from equal efficiency as HUVECS to donors of whom 
the cells produced five-fold less tubes. It also occurred to us that cells from some donors 
started to form capillary-like structures at a later time point than most, but in the end reached 
the same level of CLS formation (data not shown). Overall, the total tube length and the 
number of branching points correlated to each other. Since all results were taken at an 
arbitrarily chosen time point (24h) identical in case of all analyzed samples, this variability is 
present in the final quantification. Taken together, our data shows that cells from all donors 
responded to the Matrigel stimulation but with different efficiency. Yet, there was not a single 
donor from whom the cells did not respond at all.  
 
Endothelial gene expression profile in MSCs 
For further classification of EL-MSCs from different donors we analyzed endothelial-specific 
genes expression. As previously, cells were cultured for 10 days in EGM-2 on an orbital 
shaker and were then reseeded on Matrigel for another 24 hours. This relative short time of 
culture was chosen because in some cases, the Matrigel coating was completely resorbed at 
later time points, indicating donor specific matrix degrading activity. We performed qPCR on 
platelet endothelial cell adhesion molecule (CD31), vascular endothelial growth factor 
receptor 2 (KDR), von Willebrand factor (vWF) and vascular endothelial Cadherin (VE-
Cadherin) and expressed it relative to GAPDH. We found a great variability of endothelial 
marker induction in cells from different donors. Cells from all donors responded to the 
differentiation protocol with increased CD31 expression (Fig 5A), with a fold induction 
between 3 and 78. In fifteen donors out of twenty we observed increased KDR expression 
(fold induction between 16 and 1000) and twelve of the 20 donors showed increased vWF 
expression (fold induction between 2 and 18) (Fig 5B and 5C). Only six donors responded 
with significantly increased VE-Cadherin expression (fold induction between 32 and 88) 
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(Fig 5D). Not in all donors VE-cadherin expression was matched by other markers and we did 
not observe a robust correlation between total tube length or number of branching points and 
endothelial marker expression. The expression levels of all tested endothelial markers except 
KDR did not reach the level of its expression in HUVECs, however, we confirmed in our 
previous study with immunostainings [16], that these expression levels were relevant.  
For further analysis we divided twenty donors into four groups, scoring their endothelial 
differentiation capability based on changes in CD31 and KDR expression: 25% of worst 
performing donors received grade 1, next 25% grade 2, third group grade 3 and the best 
performing 25% donors received grade 4 (Supplementary Table 1). These groups of samples 
allowed to discriminate between bone marrow-derived hMSCs able to differentiate efficiently 
into the endothelial lineage (grade 4) from hMSCs that do not have this differentiation 
capacity (grade 1) and were further used to find differences in gene expression of hMSCs at 
proliferating state. 
 
Correlation between gene expression profile and ability to show endothelial gene expression 
We investigated whether the differential expression of marker genes in endothelial-like cells 
is reflected in the gene expression repertoire of their undifferentiated ancestors, in other words 
we tried to find genes predictive of the efficacy of induction of endothelial marker gene 
expression. To this end, we compared the expression profiles of MSCs between the four 
different groups defined above. The top 30 genes from the resulting list were ranked on p 
value (Table 1). Interestingly, among the listed genes we found three that are directly 
involved in VEGF signaling pathway: CRYAB, EGR3, IL7R; four that are typical for 
endothelial cells: GFPT2, EGR3, ILR7, MEIS2; four involved in the proliferation and 
migration of cancer cells: SULF1, CRYZ, CA12, PHLDA1 and six involved in cardiovascular 
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system development and diseases: ELN, CRYAB, SLC5A3, CA12, PHLDA1, FHL1 (Table 
2). 
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DISCUSSION 
Human mesenchymal stromal cells are multipotent cells with well acknowledged capacity to 
differentiate into cell types from several lineages [5-7,36,37] and have therefore been 
extensively tested in various tissue engineering applications. One of the important questions 
that appear concerning the application of differentiated MSCs is the true nature of cells 
obtained upon various differentiation protocols. MSCs have been shown to differentiate 
towards various cell types based both on the expression of characteristic markers in vitro as 
well as on their ability to regenerate specific tissues in vivo. Still, the mechanism lying behind 
the ability of implanted MSCs to regenerate or improve regeneration of various tissues is not 
fully explored [38]. In our previous work [16], we demonstrated that MSCs can differentiate 
towards endothelial-like cells. We based this conclusion on both the increased expression of 
endothelial markers in EL-MSCs, confirmed additionally by immunostainings, and on the 
effect on construct vascularization when EL-MSCs were implanted. Nonetheless, we did not 
claim to obtain endothelial cells from MSCs but rather cells that are able to replace them in 
therapeutic applications. To prove the usefulness of the developed protocol, its robustness 
must be showed with respect to overpowering the variability among cells obtained from 
different donors.. 
In this study we isolated and characterized hMSCs from 20 independent donors. First we 
analyzed cell performance in a Matrigel assay where we found that the efficiency in tube 
formation was not the same between different donors. According to our observations at 
various time points (data not shown), some of the differences in results could be caused by the 
chosen observation time that was set for 24 hours after seeding. Since cells from different 
donors started to form CLSs at different time points, the results were not fully reflecting the 
absolute potential of hMSCs to form CLSs. The differences between donors occurred rather 
as a result of differences in the speed of attachment and migration. CLS network formation on 
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Matrigel occurs as an effect of cells attaching to the gel surface, spreading and getting in 
contact with each other and with extracellular matrix (ECM). Since the cells used in this assay 
were freshly trypsinized differences were likely to occur at the level of molecules responsible 
for ECM binding on the cell surface. Therefore, it was to be expected that the speed of 
attachment may vary depending on the sample. Another reason for the differences in the 
speed of cell attachment and migration can be explained by the age of the donors, as Kasper et 
al. [39] demonstrated that those parameters are strongly correlated. Although donor variation 
in CLS formation was observed, CLS maturity was reached in all cases within 24 hours. 
Endothelial cells of all origins are able to form tubules spontaneously [40] but the exact time 
of this event can be different for various cells of this type [41]. Thus, since EL-MSCs from all 
investigated donors responded to Matrigel stimulation, the differences in time of response 
does not mean that those cells did not undergo endothelial differentiation.  
Next we analyzed the gene expression profile of differentiated hMSCs with respect to 
expression of endothelial markers: CD31, KDR, vWF and VE-Cadherin. Here we found great 
variability of endothelial marker induction in cells from different donors. Up-regulation in the 
expression of one selected gene was not necessarily followed by up-regulation of the others. 
This phenomenon could be explained by the single time point that we have chosen for 
analysis. Cells form various donors were most likely at different level of differentiation after 
24 hours of Matrigel culture. As demonstrated by Levenberg at al. [42], the expression of 
endothelial specific genes in differentiating cells is not correlated with each other in time. 
Therefore, for microarray studies we decided to focus on these two genes, namely CD31 and 
KDR, which are commonly used as endothelial markers and for which up-regulation occurred 
in most of the donors.  
Based on the performed microarray study we selected 30 genes that were differentially 
expressed. Among those we identified 17 genes whose expression is involved in VEGF 
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signaling, expression of markers typical for endothelial cells, development and diseases of 
cardiovascular system as well as cell proliferation and migration in malignant cancers. 
hMSCs from various donors have in general a similar gene expression profile in their 
undifferentiated state. Therefore, many differentially expressed genes connected with 
endothelial cells might give the possibility to predict the potential of a given hMSC for 
endothelial differentiation. We consider that from genes involved in VEGF signaling the up-
regulation of expression of EGR3 in proliferating hMSCs is of major importance. EGR3 is a 
transcription factor that plays a positive role in VEGFR1 transcription [43]. The abundance of 
EGR3 in hMSCs might make them more responsive to VEGF present in culture media and by 
that more prone to become EL-MSCs. Additionally EGR3 is a critical determinant of VEGF 
signaling in activated endothelial cells where the EGR3 expression level influences VEGF-
mediated proliferation, migration, and tube formation [44]. It is possible that EGR3 plays a 
similar role in differentiating hMSCs. The observed down-regulation of two other genes 
involved in VEGF signaling that we found as differentially expressed in MSCs is probably 
connected to the fact that both CRYAB and IL7R are playing a role in VEGF signaling 
mostly in cases where cancer cells are involved [45-47]. 
Among genes that are specific to endothelial cells and were differentially expressed in 
proliferating hMSCs the expression of three was up-regulated (GFPT2, EGR3 and MEIS2) 
while one, IL7R, typical for microvascular cells, was down-regulated. Since GFPT2 [48] and 
EGR3 are typical for all endothelial cells, MEIS2 is a marker of macrovascular endothelial 
cells and is not highly expressed in microvascular endothelial cells [49] and IL7R is present 
on microvascular endothelial cells [50] we suggest that hMSCs might be more susceptible to 
differentiate towards endothelial cells that are different in their characteristic from 
microvascular endothelial cells. 
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Our results do not allow us to draw firm conclusions about hMSC potential to differentiate 
towards endothelial cells based on the differentially expressed genes involved in cell survival, 
proliferation and migration or the one involved in cardiovascular system development and 
diseases. Further studies are necessary to conclude whether differences in these genes’ 
expression are anyhow important for their application as therapeutic cells.  
The applicability of hMSCs in regenerative medicine depends largely on their ability to 
expand in vitro without losing their potential to differentiate before reaching clinically 
relevant cell number. Since EL-MSCs are required in rather large quantities to be used in TE 
applications, we performed a series of experiments to check whether extended proliferation 
will influence multipotency of hMSCs. To compare our results with the ones previously 
obtained [1,51], we evaluated osteogenic and adipogenic differentiation along with 
endothelial differentiation on cells from all 10 passages. Our results concerning the 
osteogenic and adipogenic potential of serially passaged hMSCs were consistent with those 
obtained earlier. Interestingly, the endothelial differentiation was not influenced by a 
prolonged expansion phase, as showed both in the Matrigel assay as well as in the gene 
expression studies. In the Matrigel assay we observed that the parameters of structures formed 
after prolonged expansion are donor-dependent, therefore no conclusions about the influence 
of passage number can be made. According to our unpublished results we can conclude that in 
this assay it is rather the number of seeded cells that is crucial for the final outcome, therefore 
even cells from late passages  that did not lose their ability to attach, spread and migrate could 
efficiently form CLSs. Cells from one investigated donor stopped proliferating at passage 6 
which excluded them from the endothelial senescence study but in all other cases no negative 
effect of in vitro expansion on endothelial potential was observed. To our knowledge, this is 
the first observation of such phenomenon in hMSCs. From this study we conclude that 
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hMSCs can be expanded in vitro at least up to passage 6 while keeping endothelial potential 
for effective use in tissue regeneration applications.  
To summarize, our report provides several candidates for molecular markers that can be used 
for prediction of hMSC potential to differentiate into endothelial-like cells. We also showed 
that this potential is not affected by prolonged in vitro expansion as long as the cells keep 
proliferating. Altogether, our results indicate that hMSCs from various donors perform well 
enough to be considered in potential clinical applications. 
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CAPTIONS 
 
Figures 
Supplementary Figure 1. Pluripotency of hMSCs. Adipogenic differentiation (A) 
demonstrated by Oil red O staining and osteogenic differentiation (B) demonstrated by ALP 
staining. 
Figure 1. Expansion and osteogenic potential of serially passaged hMSCs. Cell 
morphology (A). CDP-Star assay was used to quantify ALP activity (B). Error bars represent 
standard deviation, * and ** denote statistical significance towards other groups (p < 0.05). 
Figure 2. Adipogenic potential of serially passaged hMSCs. Adipogenic differentiation 
was visualized by staining with Oil red O (A) and the number of adipocytes was quantified 
(B). Error bars represent standard deviation, * and ** denote statistical significance towards 
other groups (p < 0.05). 
Figure 3. Endothelial potential of serially passaged hMSCs. Capillary-like structure 
formation was observed on Matrigel (A). CD31 expression was compared using qPCR (B). 
Error bars represent standard deviation. 
Figure 4. Tube assay on Matrigel. EL-hMSCs from different donors were cultured on 
Matrigel for 24h in EGM-2 medium (A). Total tube length and number of branching points 
were compared (B).  
Figure 5. Donor variation in endothelial gene expression.  Data are represented as fold 
induction compared to gene expression level of undifferentiated MSCs from the same donor. 
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Table 1. Differentially expressed genes as identified by whole genome expression 
analysis. Donors were grouped based on their ability to differentiate into endothelial-like 
cells. Fold change between the best and poorest endothelial differentiating donors (based on 
CD31 and KDR expression) is specified in the table. Repeated gene names that appear in the 
table correspond to various probes for the same gene.  
Gene Name Gene Symbol Fold Change 
genes identified based on CD31 expression 
elastin ELN -2.05 
sulfatase 1 SULF1 -1.77 
crystallin, zeta (quinone reductase) CRYZ 1.62 
crystallin, alpha B CRYAB -1.54 
chromosome 1 open reading frame 54 C1orf54 1.46 
solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 SLC5A3 1.45 
carbonic anhydrase XII CA12 1.45 
glutamine-fructose-6-phosphate transaminase 2 GFPT2 1.44 
pleckstrin homology-like domain, family A, member 1 PHLDA1 1.44 
early growth response 3 EGR3 1.44 
carbonic anhydrase XII CA12 1.37 
elastin ELN -1.33 
solute carrier family 16, member 4 (monocarboxylic acid transporter 5) SLC16A4 1.31 
interleukin 7 receptor IL7R -1.26 
adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) ADARB1 -1.26 
stomatin STOM -1.25 
haloacid dehalogenase-like hydrolase domain containing 1A HDHD1A -1.23 
serine incorporator 5 SERINC5 1.23 
iduronate 2-sulfatase IDS 1.21 
kazrin KAZ -1.21 
genes identified based on KDR expression   
four and a half LIM domains 1 FHL1 -1.79 
four and a half LIM domains 1 FHL1 -1.74 
keratin 19 KRT19 1.69 
KIAA1199 KIAA1199 -1.45 
ferritin, heavy polypeptide 1 FTH1 -1.40 
glutaminase GLS -1.28 
Meis homeobox 2 MEIS2 1.28 
ATPase, class V, type 10D ATP10D -1.21 
endothelin receptor type A EDNRA 1.18 
structural maintenance of chromosomes 2 SMC2 1.18 
(-) in the fold change value denotes down-regulation when comparing donors with good and poor endothelial differentiation capabilities 
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Table 2. Identity and function of differentially expressed genes as identified by whole 
genome expression analysis. Donors were grouped based on their ability to differentiate into 
endothelial-like cells. 
 
↑ denotes up-regulation, ↓ denotes down-regulation when comparing donors with good and poor endothelial differentiation capabilities 
 
Gene Name and function References 
VEGF signaling 
CRYAB ↓ Crystallin alpha B, protects VEGF from proteolytic degradation, 
knockdown of CRYAB had an inhibitory effect on endothelial cells 
survival, mutations in the Cryab gene are associated with a broad variety 
of neurological, cardiac and muscular disorders 
[45,52] 
EGR3 ↑ Early growth response 3, plays a role in endothelial cell growth and 
migration, mediates VEGF activation in endothelial cells,  
[43,44] 
IL7R ↓ Interleukin 7 receptor, present on human microvascular endothelial cells, 
activation by IL7 enhances endothelial cell growth, migration and 
generation of lymphatic tubules via upregulating the expression of the 
lymphangiogenic growth factor and vascular endothelial growth factor-D, 
IL-7 regulates also VEGF-D in lung cancer cell lines, plays a role in 
rheumatoid arthritis angiogenesis, and can mediate rheumatoid arthritis 
pathogenesis 
[46,47,50,53,54] 
Characteristic for endothelial cells 
GFPT2 ↑ Glutamine-fructose-6-phosphate transaminase 2, highly active in all 
endothelial cells, expressed in most tissues involved in the development of 
diabetic late complications 
[48,55] 
EGR3 ↑ See above  
IL7R ↓ See above  
MEIS2 ↑ Meis homeobox 2, differentially expressed in placental microvascular 
endothelial cells compared with macrovascular cells, possible role in the 
development of cleft palate and cardiac septum 
[49,56] 
Cell survival, proliferation, migration and cancer malignancy 
SULF1 ↓ Sulfatase 1, selectively removes 6-O-sulfate groups from heparan sulfate 
proteoglycans and by that alters binding sites for various cytokines and 
growth factors  
[57-59] 
CRYZ ↑ Crystallin zeta (quinone reductase), enzyme with NADPH-dependent 
quinone reductase activity, involved in antiapoptotic bcl-2 overexpression 
[52,60] 
CA12 ↑ Carbonic anhydrase XII, zinc metalloenzyme that catalyzes the reversible 
hydration of carbon dioxide, expressed at high levels on various types of 
cancer cells including cancer stem cells, involved in tumour progression, 
additionally contributes to various other diseases like glaucoma and 
arteriosclerotic plaques, abundantly expressed in normal human corneal 
endothelium 
[61-64] 
PHLDA1 ↑ Pleckstrin homology-like domain, family A, member 1, Apoptosis-
associated nuclear protein, contributes to migration and proliferation in 
colon cancer cells, contributes to the development of atherosclerosis 
observed in hyperhomocysteinemia 
[65,66] 
Cardiovascular system development and diseases 
ELN ↓ Elastin, components of elastic fibers, disrubtion leads to various vascular 
diseases 
[67,68] 
CRYAB ↓ See above  
SLC5A3 ↑ Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3, 
essential for osteogenesis and bone formation, additive effects of multiple 
genetic variants of SLC5A3 on the risk of coronary artery disease 
[69,70] 
CA12 ↑ See above  
PHLDA1 ↑ See above  
FHL1 ↓ Four and a half LIM domains 1, heavily expressed in skeletal and cardiac 
muscles, plays a role in cardiovascular development, hypertrophy, 
atherosclerosis, and angiogenesis 
[71,72] 
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Supplementary Table 1. Donor comparison based on qPCR data. Grades were calculated 
based on the data distribution: 25% of worst performing donors received grade 1, next 25% 
grade 2, third group grade 3 and best 25% donors received grade 4.  
donor CD31   donor KDR 
57 4   71 4 
64 4   64 4 
49 4   59 4 
55 4   57 4 
51 4   47 4 
67 4   27 4 
47 3   74 3 
40 3   55 3 
65 3   49 3 
43 3   40 3 
71 2   67 2 
59 2   65 2 
56 2   60 2 
60 2   56 2 
78 2   51 2 
27 1   78 1 
74 1   75 1 
38 1   58 1 
58 1   43 1 
75 1   38 1 
 
 
 Page 30 of 37
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
Th
e 
ef
fe
ct
 o
f d
on
or
 v
ar
ia
tio
n 
an
d 
se
ne
sc
en
ce
 o
n 
en
do
th
el
ia
l d
iff
er
en
tia
tio
n 
of
 h
um
an
 m
es
en
ch
ym
al
 st
ro
m
al
 c
el
ls 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.06
46
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
31 
Janeczek Portalska et al.  31 
 
Figure 1. Expansion and osteogenic potential of serially passaged hMSCs. Cell morphology (A). CDP-Star assay was used to quantify ALP activity (B). Error bars represent standard 
deviation, * and ** denote statistical significance towards other groups (p < 0.05). 
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Figure 2. Adipogenic potential of serially passaged hMSCs. Adipogenic differentiation was visualized by staining with Oil red O (A) and the number of adipocytes was quantified (B). 
Error bars represent standard deviation, * and ** denote statistical significance towards other groups (p < 0.05). 
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Figure 3. Endothelial potential of serially passaged hMSCs. Capillary-like structure formation was observed on Matrigel (A). CD31 expression was compared using qPCR (B). Error bars 
represent standard deviation. 
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Figure 4. Tube assay on Matrigel. EL-hMSCs from different donors were cultured on Matrigel for 24h in EGM-2 medium (A). Total tube length and number of branching points were 
compared (B). 
 Page 34 of 37
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
Th
e 
ef
fe
ct
 o
f d
on
or
 v
ar
ia
tio
n 
an
d 
se
ne
sc
en
ce
 o
n 
en
do
th
el
ia
l d
iff
er
en
tia
tio
n 
of
 h
um
an
 m
es
en
ch
ym
al
 st
ro
m
al
 c
el
ls 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.06
46
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
35 
Janeczek Portalska et al.  35 
 
 Page 35 of 37 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
Th
e 
ef
fe
ct
 o
f d
on
or
 v
ar
ia
tio
n 
an
d 
se
ne
sc
en
ce
 o
n 
en
do
th
el
ia
l d
iff
er
en
tia
tio
n 
of
 h
um
an
 m
es
en
ch
ym
al
 st
ro
m
al
 c
el
ls 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.06
46
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
36 
Janeczek Portalska et al.  36 
Figure 5. Donor variation in endothelial gene expression.  Data are represented as fold induction compared to gene expression level of undifferentiated MSCs from the same donor. 
 Page 36 of 37
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
Th
e 
ef
fe
ct
 o
f d
on
or
 v
ar
ia
tio
n 
an
d 
se
ne
sc
en
ce
 o
n 
en
do
th
el
ia
l d
iff
er
en
tia
tio
n 
of
 h
um
an
 m
es
en
ch
ym
al
 st
ro
m
al
 c
el
ls 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
12
.06
46
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
37 
Janeczek Portalska et al.  37 
 
Supplementary Figure 1. Pluripotency of hMSCs. Adipogenic differentiation (A) demonstrated by Oil red O staining and osteogenic differentiation (B) demonstrated by ALP staining. 
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